Ind-swift Laboratories Ltd. · NSE:INDSWFTLAB
Ind-swift Laboratories — Investor Presentation (January 2026)
25 slides from Ind-swift Laboratories's investor presentation, Jan 14, 2026
Slide 1: Cover letter to stock exchanges: Investor Presentation
Ref: ISLL:CH:2026 Date: 14th January, 2026 The President The Vice President, Corporate Relationship Department Listing Compliance Department, BSE Limited National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor 25th Floor, Dalal Street, Plot No. C/2, G-Block, Mu
Slide 2: Ind-Swift Laboratories Limited Investor Presentation
Ind - Swift Laboratories Limited Leading Finished Dosage Formulation Manufacturer 1 INVESTOR PRESENTATION
Slide 3: Management Commentary
MANAGEMENT COMMENTARY “Ind-Swift Laboratories Ltd has successfully completed a historic strategic reset through the ₹1,650 Cr divestment of its API & CRAMS business. This decisive action, combined with the merger of Ind-Swift Limited into ISLL, has transformed the company into a Net Debt Free entity
Slide 4: Evolution & Transformation Journey
EVOLUTION & TRANSFORMATION JOURNEY Ind-Swift Group | Strategic Evolution 1997 1998 2004 2005 2007 2011 2012-23 Inception of Setup of API US 2nd plant USFDA PMD / ANVISA Manufacturing Subsidiary commissioned Approval USFDA Approval Ind-Swift Facility Incorporated in Jammu Approval FDA Laboratories In
Slide 5: Ind-Swift Laboratories Ltd – The Before State
IND - SWIFT LABORATORIES LTD – “The Before State” DMFs Filed across 33 Therapeutic APIs across Team Size molecules categories Incorporated in 1995 as part of the Ind-Swift Group. 30+ 2500+ 481+ 18 Built as the Group’s dedicated API & CRAMS entity. Among India’s largest standalone API manufacturers L
Slide 6: Transaction Summary & Financial Reset
TRANSACTION SUMMARY & FINANCIAL RESET Synthimed Labs Transaction Summary Strategic Rationale Slump Sale : Transaction Value : Debt Elimination: Proceeds used to repay entire external debt API & CRAMS business sold to Synthimed Labs Pvt. Ltd. Balance Sheet Reset: Transition from a leveraged profile t
Slide 7: Post-Transformation Overview
POST - TRANSFORMATION OVERVIEW Post-Transformation Overview Key Metrics • Strategic exit from API & CRAMS through a ₹1,650 Cr slump sale, making ISLL net debt-free. 750+ 520+ 38+ • Ind-Swift Limited merged into Ind-Swift Laboratories Limited Product Approvals Years of (Effective 31 March 2024, NCLT-
Slide 8: Manufacturing Infrastructure
MANUFACTURING INFRASTRUCTURE Domestic Unit Global Business Unit (GBU) Samba, J&K Derabassi, Punjab • Strategic Status: 100% Export Oriented Unit (EOU) - Primary revenue engine. • Scale: Spans ≈81,325 sq. meters. • Focus: Domestic formulations • Capabilities: Dedicated blocks for Oral Solid (Ethical,
Slide 9: R&D Capabilities
R&D CAPABILITES Infrastructure & Capabilities • Dedicated Formulation R&D Centre in Panchkula, approved by DST (Govt. of India). • 60+ specialized scientists focused on Finished Dosage development. • Strong analytical capabilities: stability studies (ICH), data profiling & analytical method validati
Slide 10: Integrated Business Lines
INTEGRATED BUSINESS LINES Infrastructure International& Capabilities Engine (Global Business Unit) Domestic Engine (India Operations) Focus: High-Value Exports & Regulated Market Comprehensive Market Coverage via multiple Strategic Verticals • Dossier-driven model for regulated & semi-regulated mark
Slide 11: Diversified Markets & Clientele
DIVERSIFIED MARKETS & CLIENTELE 53% Europe 5% Canada 5% Approx 3% Middle East Others 16% South East Asia 5% UAE 5% 8% Africa Australia 10
Slide 12: Global Market Potential
GLOBAL MARKET POTENTIAL 80 Global CMO Market Overview (In USD Billions) 73.75 70 2024 2030 60 56.09 51.91 50 40 30.88 30 20 15.73 10.48 9 10 6.65 2.13 3.6 2.03 3.99 0.83 1.33 0 UAE South Africa Australia Middle East Canada Europe USA Source Source Source Source Source Source Source • Growing demand
Slide 13: Global Product Registrations
GLOBAL PRODUCT REGISTRATIONS 88 CIS + 10 Russia 10 Canada 73 Europe 34 GCC 48 UAE 146 South East Asia 166 Africa + FWA 166 Africa + FWA 146 South East Asia 81 Latin America 81 Latin America 88 CIS + 10 Russia 48 UAE 73 Europe 39 Australia 39 Australia 34 GCC 6 New 10 Canada Zealand 6 New Zealand 12
Slide 14: Global Regulatory Landscape
GLOBAL REGULATORY LANDSCAPE Canada Russia United Kingdom Geneva UAE Taiwan Saudi Australia Regulated Markets Emerging Markets Future Regulatory Targets (Growth Triggers) UK-MHRA (United Kingdom). WHO-GMP (Geneva). 2025: Scheduled inspections for Saudi FDA (SFDA) TGA (Australia). MoH UAE. and Taiwan
Slide 15: Top Export Portfolio Mix
TOP EXPORT PORTFOLIO MIX Market Size Market Size Top Product Revenue Wise Breakup Products FY24 FY25 2024/25 2030-35 Source FY25 (INR Lakhs) (In USD Billions) (In USD Billions) Fexofenadine 7666.17 7967.32 1.5 2.1 Link 2.00% 3.00% 3.00% Atorvastatin 3189.88 4795.71 11.86 19.09 Link 6.00% 22.00% Metf
Slide 16: Upcoming Product Launch
UPCOMING PRODUCT LAUNCH Projected Products Partner Market Commercialization Market Size Market Size Source Revenue Year 2024/5 (In USD Mn) 2030 (In USD Mn) (In USD Mn) Ibuprofen Sachet Viatris Europe 12.00 FY27 112.7 164.1 Link Clarithromycin Dry Viatris Europe 6.00 FY27 2152.2 3501.43 Link Suspensi
Slide 17: Key Catalyst & Initiatives
KEY CATALYST & INITIATIVES Global Demand Surge Domestic Consumption Boom • Global pharmaceutical market expected to reach • Indian pharma market projected to reach from USD 55 USD 2,350 Billion by 2030. Source Billion USD 130 Billion by 2030, CAGR 12.25%. Source • Strong generic drug demand across r
Slide 18: Growth Rationale / Future Outlook
GROWTH RATIONALE / FUTURE OUTLOOK • Viatris Commercialization (FY27) • Commercial supplies begin in 2026, • Topline CAGR 20-25%, scaling from ₹200-220 Cr incremental revenue ₹550 Cr to ₹1,200+ Cr by FY29. expected in FY27. • CDMO to triple over 4 years (₹180 Cr → ₹550-600 Cr) driven by Greenfield Ex
Slide 19: Board of Directors
BOARD OF DIRECTORS Mr. N.R. Munjal Mr. Himanshu Jain Chairman and Managing Director Joint Managing Director • 40+ years of experience expanding the Group’s • 22+ years of experience specializing in project footprint across 85+ countries with offices in planning, financial strategy, and operational U
Slide 20: Executive Leadership Team
EXECUTIVE LEADERSHIP TEAM Mr. Varun Chabra Mr. Ravi Bhardwaj President – International Mr. Pradeep Verma Mr. Gagan Agarwal Corporate Affairs Chief Financial Officer Corporate Quality Head Marketing • 35+ Years of Experience across • 25+ years exp, expanded Quality, formulation R&D & • 29+ years exp,
Slide 21: Key Financial Metrics
KEY FINANCIAL METRICS Total Revenue (INR Cr.) EBITDA (INR Cr) & EBITDA Margins (%) PAT (INR Cr) & PAT Margins (%) 170.5 10 9 8.78 25 7.99 8 20 19.34 7 18.18 5.25% 4.69% 6 15 11.34% 167.32 5 10.87% 4 10 3 2 5 1 0 0 Q1FY26 Q2FY26 Q1FY26 Q2FY26 Q1FY26 Q2FY26 20
Slide 22: Q2 FY26 Consolidated Financial Highlights
Q2 FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS Particulars (INR Crs.) Q1 FY26 Q2 FY26 Y-o-Y Change (%) Revenue 152.73 152.64 Other Income 14.58 17.86 Total Income 167.32 170.50 1.91 Raw Material Expense 73.09 77.65 Employee Benefit Expense 32.53 36.27 Other Expenses 43.51 37.25 EBITDA 18.18 19.34 6.34 EB
Slide 23: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Equities & Liabilities (INR Cr) FY25 H1 FY26 Assets FY25 H1 FY26 Shareholder's Fund Non Current Assets Share Capital 68.74 81.61 PP&E 273.01 285.10 Reserves & Surplus 1104.22 1225.83 Total Equity 1172.97 1307.44 Deferred tax assets 44.64 44.64 Other Non - Current Assets 25
Slide 24: Stock Data
STOCK DATA As on 05-01-2026 Share Performance From 1st Jan 2025 To 1st Jan 2026 BSE: Share Price ₹ 89.90 Market Capitalization ₹ Crs 733.69 VOLUME close 140 No. of Share Outstanding 81,611,558 250 00000 Face Value ₹ 10.00 120 200 00000 52 Week High ₹ 124.45 100 52 Week Low ₹ 67.15 150 00000 80 As on
Slide 25: Thank You
ThankYou ```` Investor & Public Relations Consultant Ind Swift Laboratories Ltd. 103-8, Lodha Eternis, MIDC, SCO 850, NAC, Shivalik Enclave, Andheri East, Mumbai 400093 Manimajra, Chandigarh, Maharashtra, India. 1600101, India Phone: +91 85911 45959 Email: investor@indswiftlabs.com Email: info@confi
Ind-Swift Laboratories — Investor Presentation (January 2026) on 6ix